Bempedoic acid
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Bempedoic acid and local guidelines before prescribing.
Lipid-lowering agent
Mechanism
ATP citrate lyase inhibitor reducing hepatic cholesterol synthesis.
Uses
Hypercholesterolaemia in statin intolerance (with ezetimibe).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hyperuricaemia and gout, tendon rupture, raised creatinine.
Interactions
Simvastatin and pravastatin dose limits.
Contraindications and cautions
Gout
Monitoring
Lipids, urate
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution in severe renal impairment
Overdose and reversal
Supportive
Special advice
Check urate and LFT.
More from the textbook: uses, cautions and other points
- Bempedoic acid with ezetimibe (NICE TA694): When statins are contraindicated or not tolerated, and ezetimibe alone is not enough.
Endocrinology: Lipids and obesity - Bempedoic acid + ezetimibe | When statins are contraindicated or not tolerated (NICE TA694).
Endocrinology: Lipids and obesity - Bempedoic acid - blocks cholesterol synthesis upstream of HMG-CoA reductase (activated in the liver, so fewer muscle effects); can raise urate.
Cardiology: Anatomy Physiology and Pharmacology - True intolerance of all statins is uncommon. If it occurs, use ezetimibe, bempedoic acid or inclisiran.
Endocrinology: Lipids and obesity - Normal or mildly raised CK - consider a break and re-challenge, a lower dose, or a different statin. Don't abandon lipid lowering - consider ezetimibe, bempedoic acid or inclisiran.
Neurology: Neuromuscular disease - PCSK9 inhibitors (evolocumab, alirocumab) or inclisiran if LDL remains high (NICE criteria); bempedoic acid in some.
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions - Ezetimibe blocks intestinal cholesterol absorption (NPC1L1); bempedoic acid inhibits ATP citrate lyase (upstream of HMG-CoA reductase); fibrates activate PPAR-α (lower triglycerides).
Biochemistry: Metabolism of carbohydrates, lipids and proteins
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Lipids and obesity (3 mentions)
- Neurology: Neuromuscular disease (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (1 mention)
- Biochemistry: Metabolism of carbohydrates, lipids and proteins (1 mention)